Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

6.760 -0.180 (-2.59%)
Streaming Delayed Price Updated: 3:27 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,332,265
Open 6.860
Bid (Size) 6.760 (14)
Ask (Size) 6.770 (46)
Prev. Close 6.940
Today's Range 6.712 - 6.900
52wk Range 4.970 - 15.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Recursion Pharmaceuticals Stock a Buy?
It largely depends on your investing style. 
Via The Motley Fool
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Via Benzinga

Performance

YTD
-31.51%
-31.51%
1 Month
-5.59%
-5.59%
3 Month
-26.12%
-26.12%
6 Month
-36.53%
-36.53%
1 Year
-16.85%
-16.85%

More News

Read More
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
These AI-Related Stocks Were Down +10% Week Ending September 6
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Via Benzinga
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
Via Benzinga
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Via Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
Via The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.